Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 12/20 | 0.54 |
| ▸ | DRD2 | P14416 | 11/20 | 0.54 |
| ▸ | HTR2A | P28223 | 8/20 | 0.53 |
| ▸ | HTR2C | P28335 | 8/20 | 0.53 |
| ▸ | HTR2B | P41595 | 8/20 | 0.53 |
| ▸ | PRKAB2 | O43741 | 2/20 | 0.44 |
| ▸ | PRKAG1 | P54619 | 2/20 | 0.44 |
| ▸ | PRKAA2 | P54646 | 2/20 | 0.44 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.44 |
| ▸ | PRKAG3 | Q9UGI9 | 2/20 | 0.44 |
| ▸ | PRKAG2 | Q9UGJ0 | 2/20 | 0.44 |
| ▸ | PRKAB1 | Q9Y478 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | NGFR | P08138 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.36 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7470402 | 1.00 | HTR1A (0.54) | HTR1ADRD2HTR2AHTR2CHTR2B | |
| SCHEMBL7681490 | 0.79 | HTR1A (0.47) | HTR1ADRD2HTR2AHTR2CHTR2B | |
| SCHEMBL7681499 | 0.79 | HTR1A (0.47) | HTR1ADRD2HTR2AHTR2CHTR2B | |
| SCHEMBL24149616 | 0.76 | KDM4E (0.48) | HTR1ADRD2HTR2AHTR2CHTR2B | |
| SCHEMBL7035903 | 0.76 | KDM4E (0.48) | HTR1ADRD2HTR2AHTR2CHTR2B | |
| SCHEMBL7466691 | 0.74 | HTR1A (0.48) | HTR1ADRD2HTR2AHTR2CHTR2B | |
| SCHEMBL7466700 | 0.74 | HTR1A (0.48) | HTR1ADRD2HTR2AHTR2CHTR2B | |
| SCHEMBL3761317 | 0.70 | PRKAB2 (0.43) | HTR1ADRD2HTR2AHTR2CHTR2B | |
| SCHEMBL8595403 | 0.70 | PRKAB2 (0.43) | HTR1ADRD2HTR2AHTR2CHTR2B | |
| SCHEMBL9384176 | 0.69 | KDM4E (0.49) | KDM4EALDH1A1HSD17B10LMNANGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0876372-B1 | HETEROARYLCARBOXAMIDE DERIVATIVES | KNOLL GMBH (DE) | 2002-03-06 | — | — | EP | disclosed |
| US-6353002-B2 | DIOXINOINDOLE AND THIENOBENZODIOXIN COMPOUNDS WHICH ARE HT3 RECEPTOR ANTAGONISTS AND ARE USED TO TREAT CENTRAL NERVOUS SYSTEM DISORDERS | KNOLL AKTIENGESELLSCHAFT (DE) | 2002-03-05 | — | — | US | disclosed |
| US-20010008903-A1 | Therapeutic agents | BIRCH ALAN MARTIN (GB) | 2001-07-19 | — | — | US | disclosed |
| US-6201004-B1 | CENTRAL NERVOUS SYSTEM, PSYCHOLOGICAL, EATING, CARDIOVASCULAR, BRAIN, AND GASTROINTESTINAL DISORDERS | KNOLL AKTIENGESELLSCHAFT (DE) | 2001-03-13 | — | — | US | disclosed |
| US-6107310-A | PSYCHOLOGICAL DISORDERS | KNOLL AKTIENGESELLSCHAFT (DE) | 2000-08-22 | — | — | US | disclosed |
| EP-0966470-A1 | DIOXINO DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | KNOLL AKTIENGESELLSCHAFT (DE) | 1999-12-29 | — | — | EP | disclosed |
| EP-0876372-A1 | HETEROARYLCARBOXAMIDE DERIVATIVES | KNOLL AKTIENGESELLSCHAFT (DE) | 1998-11-11 | — | — | EP | disclosed |
| WO-1998040386-A1 | DIOXINO DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | KNOLL AKTIENGESELLSCHAFT (DE) | 1998-09-17 | — | — | WO | disclosed |
| WO-1997023485-A1 | HETEROARYLCARBOXAMIDE DERIVATIVES | KNOLL AKTIENGESELLSCHAFT (DE) | 1997-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010008903-A1 | Therapeutic agents | GPR119, SNCA, HTR2B | HTR1A 5/4885DRD2 94/4885HTR2A 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.